Aspo’s Q1 results beat estimates. Uncertainty persists around H2, but we are now more confident towa...
Q1 profitability fell short of expectations and Eltel also removed guidance due to inflation.
Sales above in all three consolidated holdings Loss in Point, profit in Företagsparken EPRA NRV per ...
Q1 2022 PBLL came in DKK 31 (21%) below our estimate, mainly led by a DKK 25m miss on low quality ma...
Redeye comments on the Q1 report from Vicore and give our view of recent events in the company.
Q1'22 Redsense Medical rapporterade nettoomsättning på 3,1 mkr i Q1'22, upp från 0,7 mkr i Q1'21, mo...
Redeye states that the company’s future, Managed Services, continued its strong momentum in Q1.
Q1 marked a return to normal gross margins NWT ramp-up lagging expectations, sales down 7-3% 15-10x ...
Q-linea’s partner Thermo Fisher is launching ASTar in Europe.
Redeye raises its Base Case and forecasts following a Q1 report beating our estimates significantly.
79% sales growth, of which 27% organic Adj. EBITDA SEK 2.
Redeye will likely retain its positive view on Transtema following a Q1 report with comparable figur...
Net operating income -1% vs ABGSCe, -3% vs cons. +0.
Redeye updates estimates and valuation post Stillfront’s Q1-results which came in above our expectat...
Adj. EBIT +7% vs ABGSC, +11% vs cons UA/sales to increase to 35% in Q2… …lowering profit short term,...
Cibus posted Q1 net operating income of EUR 21.8m, up 20% y/y on the back of acquisitions and 2% abo...
Redeye gives its initial take of Paynova’s first-quarter report for 2022, which was above our growth...
Q1 sales +27% vs ABGSC, a growth of 54% y-o-y Positive EBITDA at SEK 1.
ESG activities In 2022, the company renewed its sustainability strategy and will in the forthcoming ...
Redeye finds that Westpay’s report was slightly better than expected in terms of revenue and margins...
